8-K: Turnstone Biologics Completes Merger, Goes Private

Turnstone Biologics Corp. has completed its merger with XOMA Royalty Corporation, becoming a wholly-owned subsidiary and delisting from Nasdaq.

Summary

• Turnstone Biologics Corp. (the Company) completed its merger with XRA 3 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation (Purchaser), on August 11, 2025.
• The merger followed a successful tender offer by Purchaser to acquire all outstanding shares of the Company's common stock.
• The tender offer, which expired on August 7, 2025, resulted in 17,192,002 shares being validly tendered and not withdrawn, representing approximately 74% of the outstanding shares.
• Shareholders received an offer price of $0.34 per share in cash, plus one non-transferable contractual contingent value right (CVR) for each share.
• The CVRs represent the right to receive potential future cash payments based on 'Legacy Receivable Amount' and 'Net Cash Excess', minus 'Net Cash Shortfall'.
• The 'Legacy Receivable Amount' includes up to $850,000 from Canadian tax refunds and up to $260,000 from a security deposit return, totaling up to $1,110,000.
• The Company also completed an Asset Purchase Agreement with H. Lee Moffitt Cancer Center and Research Institute, Inc. on August 11, 2025, receiving approximately $3.0 million, of which $1.8 million was placed into an escrow account.
• Following the merger, the Company became a wholly-owned subsidiary of Purchaser, leading to its delisting from The Nasdaq Capital Market and termination of its SEC reporting obligations.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the merger provides an exit for public shareholders, the CVRs are highly speculative and non-transferable, and the company's delisting removes public liquidity. The outcome was expected given prior disclosures.

Positives

• Successful completion of the merger provides liquidity to former public shareholders through the cash component of the offer.
• The inclusion of a Contingent Value Right (CVR) offers former shareholders potential future payments tied to specific financial outcomes, such as tax receivables and net cash adjustments.

Negatives

• The Company's common stock has been delisted from Nasdaq, eliminating public trading and liquidity for shareholders.
• CVRs are non-transferable (with limited exceptions) and highly speculative, with no assurance that holders will receive any payments.
• Public shareholders lose direct ownership and voting rights as the Company becomes a wholly-owned subsidiary.

Risks

• CVR payments are highly speculative and there is no assurance that holders will receive any payments under the CVR Agreement.
• The CVRs are non-transferable, limiting the ability of holders to monetize their rights prior to any potential payment.
• The value of CVR payments depends on the realization of 'Legacy Receivable Amount' and the calculation of 'Net Cash Excess' or 'Net Cash Shortfall', which are subject to future events and calculations.

Future Outlook

The Company will operate as a wholly-owned private subsidiary of XOMA Royalty Corporation. Future financial outcomes for former public shareholders are tied to the highly speculative and non-transferable Contingent Value Rights (CVRs), which may yield additional cash payments based on specific legacy receivables and net cash adjustments until the CVR expiration date of August 11, 2026.

Industry Context

This filing represents a specific corporate acquisition and consolidation within the biologics sector, rather than a broad industry trend. It signifies a strategic move by XOMA Royalty Corporation to integrate Turnstone Biologics into its portfolio, potentially leveraging Turnstone's assets and intellectual property under a private structure.

Management Changes

Corporate Governance

Related Party Transactions

• The Asset Purchase Agreement with H. Lee Moffitt Cancer Center and Research Institute, Inc. (Moffitt) involved Moffitt assuming certain obligations of the Company under the Myst Merger Agreement. Turnstone received approximately $3.0 million to offset its obligations to Moffitt under the Alliance Agreement, with $1.8 million placed into escrow.

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs, but lost liquidity due to delisting and now hold speculative, non-transferable CVRs.
• Company (Turnstone Biologics Corp.): Transitioned from a publicly traded entity to a wholly-owned private subsidiary, reducing regulatory and reporting burdens.
• XOMA Royalty Corporation: Successfully acquired Turnstone Biologics, expanding its portfolio and potentially leveraging Turnstone's assets.

Next Steps

• The Company will be delisted from The Nasdaq Capital Market.
• The Surviving Corporation intends to file Form 15 with the SEC to terminate registration of shares under Section 12(g) and suspend reporting obligations.
• The escrow amount of approximately $1.8 million from the Asset Purchase Agreement will be released to the Company.
• Potential future payments to CVR holders will occur no later than 30 days following the final determination of Net Cash Excess or receipt of Legacy Receivable Amount, with the CVR period ending on August 11, 2026.

Key Dates

Keywords

Merger, Acquisition, Biologics, Nasdaq Delisting, Contingent Value Rights, CVR, XOMA Royalty Corporation, Turnstone Biologics, SEC Filing, 8-K